Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

Glioblastoma is the most common primary malignant brain tumor of adults and one of the most lethal of all cancers. Patients with this disease have a median survival of 15 months from the time of diagnosis despite surgery, radiation, and chemotherapy. New treatment approaches are needed. Recent works suggest that glioblastoma patients may benefit from molecularly targeted therapies. Here, we address the compelling need for identification of new molecular targets. Leveraging global gene expression data from two independent sets of clinical tumor samples (n = 55 and n = 65), we identify a gene coexpression module in glioblastoma that is also present in breast cancer and significantly overlaps with the…

• DR
  Damon Runyon Cancer Research Foundation
• AB
  Accelerate Brain Cancer Cure
• EL
  Eli Lilly and Company
• BT
  Brain Tumor Funders' Collaborative
• ZF
  Ziering Family Foundation
• BN
  Barrow Neurological Foundation
• NI
  National Institutes of Health
• UO
  University of California, Los Angeles
• NC
  National Cancer Institute

  Award: CA119347